| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(3 months ago) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(3 months ago) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(5 years from now) | |
Loseasonique is owned by Teva Branded Pharm.
Loseasonique contains Ethinyl Estradiol; Levonorgestrel.
Loseasonique has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Loseasonique are:
- US7615545
- US7858605
Loseasonique was authorised for market use on 24 October, 2008.
Loseasonique is available in tablet;oral dosage forms.
Loseasonique can be used as prevention of pregnancy.
The generics of Loseasonique are possible to be released after 05 December, 2028.
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 24 October, 2008
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
LOSEASONIQUE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic